3,271 reports of this reaction
1.6% of all METOCLOPRAMIDE HYDROCHLORIDE reports
#13 most reported adverse reaction
MOVEMENT DISORDER is the #13 most commonly reported adverse reaction for METOCLOPRAMIDE HYDROCHLORIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 3,271 FDA adverse event reports linking METOCLOPRAMIDE HYDROCHLORIDE to MOVEMENT DISORDER. This represents approximately 1.6% of all 206,778 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE HYDROCHLORIDE who experience movement disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOVEMENT DISORDER is a less commonly reported adverse event for METOCLOPRAMIDE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to movement disorder, the following adverse reactions have been reported for METOCLOPRAMIDE HYDROCHLORIDE:
The following drugs have also been linked to movement disorder in FDA adverse event reports:
MOVEMENT DISORDER has been reported as an adverse event in 3,271 FDA reports for METOCLOPRAMIDE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOVEMENT DISORDER accounts for approximately 1.6% of all adverse event reports for METOCLOPRAMIDE HYDROCHLORIDE, making it a notable side effect.
If you experience movement disorder while taking METOCLOPRAMIDE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.